559 related articles for article (PubMed ID: 10430060)
1. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.
Cowan KH; Moscow JA; Huang H; Zujewski JA; O'Shaughnessy J; Sorrentino B; Hines K; Carter C; Schneider E; Cusack G; Noone M; Dunbar C; Steinberg S; Wilson W; Goldspiel B; Read EJ; Leitman SF; McDonagh K; Chow C; Abati A; Chiang Y; Chang YN; Gottesman MM; Pastan I; Nienhuis A
Clin Cancer Res; 1999 Jul; 5(7):1619-28. PubMed ID: 10430060
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients.
Takahashi S; Aiba K; Ito Y; Hatake K; Nakane M; Kobayashi T; Minowa S; Shibata H; Mitsuhashi J; Tsukahara S; Ishikawa E; Suzuki R; Tsuruo T; Sugimoto Y
Cancer Sci; 2007 Oct; 98(10):1609-16. PubMed ID: 17683514
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer.
Rahman Z; Kavanagh J; Champlin R; Giles R; Hanania E; Fu S; Zu Z; Mehra R; Holmes F; Kudelka A; Claxton D; Verschraegen C; Gajewski J; Andreeff M; Heimfeld S; Berenson R; Ellerson D; Calvert L; Mechetner E; Holzmayer T; Dayne A; Hamer J; Bachier C; Ostrove J; Deisseroth A
Clin Cancer Res; 1998 Nov; 4(11):2717-21. PubMed ID: 9829734
[TBL] [Abstract][Full Text] [Related]
4. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
5. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene.
Hanania EG; Fu S; Zu Z; Hegewisch-Becker S; Korbling M; Hester J; Durett A; Andreeff M; Mechetner E; Holzmayer T
Gene Ther; 1995 Jun; 2(4):285-94. PubMed ID: 7552989
[TBL] [Abstract][Full Text] [Related]
8. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
Prince HM; Gardyn J; Millward MJ; Rischin D; Francis P; Gates P; Chapple P; Quinn M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P; Brettell M; Toner GC
Bone Marrow Transplant; 1999 Mar; 23(5):427-35. PubMed ID: 10100555
[TBL] [Abstract][Full Text] [Related]
10. Cytokine mobilization of peripheral blood stem cells in patients with Gaucher disease with a view to gene therapy.
Nimgaonkar M; Mierski J; Beeler M; Kemp A; Lancia J; Mannion-Henderson J; Mohney T; Bahnson A; Rice E; Ball ED
Exp Hematol; 1995 Dec; 23(14):1633-41. PubMed ID: 8542958
[TBL] [Abstract][Full Text] [Related]
11. Persistent low-level engraftment of rhesus peripheral blood progenitor cells transduced with the fanconi anemia C gene after conditioning with low-dose irradiation.
Kang EM; Hanazano Y; Frare P; Vanin EF; De Witte M; Metzger M; Liu JM; Tisdale JF
Mol Ther; 2001 Jun; 3(6):911-9. PubMed ID: 11407905
[TBL] [Abstract][Full Text] [Related]
12. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.
Weaver CH; Schwartzberg LS; Birch R; Greco FA; Hainsworth J; Drapkin R; Campos L; Grapski R; Schwerkoske J; Lautersztain J; Hazelton B; Schnell F; Babcock W; Buckner CD
Biol Blood Marrow Transplant; 1997 Jun; 3(2):83-90. PubMed ID: 9267668
[TBL] [Abstract][Full Text] [Related]
13. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V
Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma.
Alici E; Björkstrand B; Treschow A; Aints A; Smith CI; Gahrton G; Dilber MS
Cancer Gene Ther; 2007 Mar; 14(3):227-32. PubMed ID: 17082794
[TBL] [Abstract][Full Text] [Related]
15. Comparison of retroviral transduction efficiency in CD34+ cells derived from bone marrow versus G-CSF-mobilized or G-CSF plus stem cell factor-mobilized peripheral blood in nonhuman primates.
Hematti P; Tuchman S; Larochelle A; Metzger ME; Donahue RE; Tisdale JF
Stem Cells; 2004; 22(6):1062-9. PubMed ID: 15536196
[TBL] [Abstract][Full Text] [Related]
16. In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate.
Mitsuhashi J; Hosoyama H; Tsukahara S; Katayama K; Noguchi K; Ito Y; Hatake K; Aiba K; Takahashi S; Sugimoto Y
J Gene Med; 2010 Jul; 12(7):596-603. PubMed ID: 20533531
[TBL] [Abstract][Full Text] [Related]
17. Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer.
O'Shaughnessy JA; Cowan KH; Nienhuis AW; McDonagh KT; Sorrentino BP; Dunbar CE; Chiang Y; Wilson W; Goldspiel B; Kohler D
Hum Gene Ther; 1994 Jul; 5(7):891-911. PubMed ID: 7526902
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase.
Cornetta K; Croop J; Dropcho E; Abonour R; Kieran MW; Kreissman S; Reeves L; Erickson LC; Williams DA
Cancer Gene Ther; 2006 Sep; 13(9):886-95. PubMed ID: 16645619
[TBL] [Abstract][Full Text] [Related]
19. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer.
Ford C; Spitzer G; Reilly W; Adkins D
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-81-S17-86. PubMed ID: 9374101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
